Litcius/Paper detail

Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation

Bruno Maucherat, N. Varmenot, Vincent Fleury, Hélène Senellart, Caroline Rousseau

2020Clinical Nuclear Medicine10 citationsDOI

Abstract

ABSTRACT: Radiopharmaceutical extravasation is a known nuclear medicine adverse effect, mostly with no complication in case of diagnostic radiopharmaceutical. However, a therapeutic radiopharmaceutical extravasation may have clinical consequences and must be treated quickly and effectively. We report here a case of 177Lu-DOTA0-Tyr3-octreotate extravasation.

Topics & Concepts

ExtravasationMedicineAdverse effectComplicationNuclear medicineSurgeryInternal medicinePathologyChemotherapy-related skin toxicityNeuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications
Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation | Litcius